HC Wainwright Lowers Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON) – Equities research analysts at HC Wainwright lowered their FY2029 earnings estimates for Disc Medicine in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst D. Tsao now expects that the company will earn $1.03 per share for the year, down from their prior forecast of $1.06. HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($6.62) per share. HC Wainwright also issued estimates for Disc Medicine’s FY2030 earnings at $7.34 EPS.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.17.

Other analysts have also issued research reports about the company. Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Wedbush reiterated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Finally, Morgan Stanley increased their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.00.

Disc Medicine Price Performance

NASDAQ IRON opened at $77.44 on Friday. Disc Medicine has a twelve month low of $40.00 and a twelve month high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The stock has a market capitalization of $2.96 billion, a PE ratio of -11.77 and a beta of 1.00. The stock has a 50-day simple moving average of $73.44 and a 200 day simple moving average of $69.73.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming acquired a new stake in Disc Medicine during the second quarter valued at approximately $25,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Disc Medicine in the 4th quarter worth approximately $33,000. KBC Group NV bought a new position in shares of Disc Medicine during the 4th quarter worth approximately $80,000. Persistent Asset Partners Ltd bought a new position in shares of Disc Medicine during the 4th quarter worth approximately $141,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after buying an additional 490 shares during the period. 83.70% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Disc Medicine

In other news, insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $70.22, for a total transaction of $526,650.00. Following the completion of the transaction, the insider directly owned 52,173 shares of the company’s stock, valued at approximately $3,663,588.06. This trade represents a 12.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John D. Quisel sold 34,000 shares of Disc Medicine stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the sale, the chief executive officer owned 226,064 shares in the company, valued at approximately $15,871,953.44. This trade represents a 13.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 105,712 shares of company stock valued at $7,597,536. Company insiders own 3.76% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.